Cargando…
Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers
BACKGROUND: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of this st...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320985/ https://www.ncbi.nlm.nih.gov/pubmed/37407982 http://dx.doi.org/10.1186/s12885-023-11115-7 |
_version_ | 1785068544605552640 |
---|---|
author | Günther, Maximilian Hentschel, Leopold Schuler, Markus Müller, Theresa Schütte, Katharina Ko, Yon-Dschun Schmidt-Wolf, Ingo Jaehde, Ulrich |
author_facet | Günther, Maximilian Hentschel, Leopold Schuler, Markus Müller, Theresa Schütte, Katharina Ko, Yon-Dschun Schmidt-Wolf, Ingo Jaehde, Ulrich |
author_sort | Günther, Maximilian |
collection | PubMed |
description | BACKGROUND: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of this study was the development of disease-specific PRO-CTCAE item sets for patients with breast cancer (BC), multiple myeloma (MM), and prostate cancer (PC). METHODS: The cross-sectional survey was conducted at three German outpatient cancer centers. Prevalence and importance of the 78 PRO-CTCAE symptoms were assessed using a patient questionnaire. To select the most relevant PRO-CTCAE items for each tumor entity, symptoms were ranked based on patient answers. RESULTS: 101 patients with BC, 107 with MM, and 66 with PC participated. The final item sets contained 21 symptoms (BC) or 19 symptoms (MM and PC), respectively. Eight symptoms (fatigue, muscle pain, insomnia, joint pain, general pain, dizziness, shortness of breath, and swelling) were represented in all three item sets. Fatigue was the symptom with the highest ranking across item sets followed by insomnia. Symptoms with the highest rankings represented in only one item set were symptoms affecting the urogenital system in the PC item set, blurred vision in the BC item set, and decreased appetite in the MM item set. CONCLUSIONS: Individual PRO-CTCAE item sets for a German patient population were developed for the three tumor entities on the basis of patients’ differences in symptom profiles and perceptions. The quality and psychometric criteria of the newly compiled item sets should be evaluated in validation studies. |
format | Online Article Text |
id | pubmed-10320985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103209852023-07-06 Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers Günther, Maximilian Hentschel, Leopold Schuler, Markus Müller, Theresa Schütte, Katharina Ko, Yon-Dschun Schmidt-Wolf, Ingo Jaehde, Ulrich BMC Cancer Research BACKGROUND: To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of this study was the development of disease-specific PRO-CTCAE item sets for patients with breast cancer (BC), multiple myeloma (MM), and prostate cancer (PC). METHODS: The cross-sectional survey was conducted at three German outpatient cancer centers. Prevalence and importance of the 78 PRO-CTCAE symptoms were assessed using a patient questionnaire. To select the most relevant PRO-CTCAE items for each tumor entity, symptoms were ranked based on patient answers. RESULTS: 101 patients with BC, 107 with MM, and 66 with PC participated. The final item sets contained 21 symptoms (BC) or 19 symptoms (MM and PC), respectively. Eight symptoms (fatigue, muscle pain, insomnia, joint pain, general pain, dizziness, shortness of breath, and swelling) were represented in all three item sets. Fatigue was the symptom with the highest ranking across item sets followed by insomnia. Symptoms with the highest rankings represented in only one item set were symptoms affecting the urogenital system in the PC item set, blurred vision in the BC item set, and decreased appetite in the MM item set. CONCLUSIONS: Individual PRO-CTCAE item sets for a German patient population were developed for the three tumor entities on the basis of patients’ differences in symptom profiles and perceptions. The quality and psychometric criteria of the newly compiled item sets should be evaluated in validation studies. BioMed Central 2023-07-05 /pmc/articles/PMC10320985/ /pubmed/37407982 http://dx.doi.org/10.1186/s12885-023-11115-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Günther, Maximilian Hentschel, Leopold Schuler, Markus Müller, Theresa Schütte, Katharina Ko, Yon-Dschun Schmidt-Wolf, Ingo Jaehde, Ulrich Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers |
title | Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers |
title_full | Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers |
title_fullStr | Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers |
title_full_unstemmed | Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers |
title_short | Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers |
title_sort | developing tumor-specific pro-ctcae item sets: analysis of a cross-sectional survey in three german outpatient cancer centers |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320985/ https://www.ncbi.nlm.nih.gov/pubmed/37407982 http://dx.doi.org/10.1186/s12885-023-11115-7 |
work_keys_str_mv | AT gunthermaximilian developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT hentschelleopold developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT schulermarkus developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT mullertheresa developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT schuttekatharina developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT koyondschun developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT schmidtwolfingo developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters AT jaehdeulrich developingtumorspecificproctcaeitemsetsanalysisofacrosssectionalsurveyinthreegermanoutpatientcancercenters |